Since the availability of recombinant human GH (rhGH) in 1985, a wide range of conditions associated with decreased growth, including GH deficiency (GHD), Turner syndrome (TS), Noonan syndrome (NS), children born small for gestational age (SGA), Prader-Willi syndrome (PWS), idiopathic short stature (ISS), and SHOX (short stature homeobox) gene haploinsufficiency have been approved by the United States Food and Drug Administration (FDA) for treatment [1-4]. The gene discussed is SHOX; the disease is Noonan syndrome.